Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov 30, 2016	Xencor, Inc. Announces Proposed Public Offering of Common Stock MONROVIA, Calif. , Nov. 30, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to	View HTML Xencor, Inc. Announces Proposed Public Offering of Common Stock 13.6 KB
Toggle SummaryNov 13, 2016	Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting - 9 of 11 patients (82%) achieved an initial response to therapy within 2 weeks of first dose --- 5 patients have attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -- Xencor management to host conference call today at 6:00 p.m. EST -	View HTML Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting 94.6 KB
Toggle SummaryNov 11, 2016	Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting MONROVIA, Calif. , Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical	View HTML Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 23.1 KB
Toggle SummaryNov 02, 2016	Xencor Reports Third Quarter 2016 Financial Results MONROVIA, Calif. , Nov. 2, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the third	View HTML Xencor Reports Third Quarter 2016 Financial Results 89.7 KB
Toggle SummaryOct 31, 2016	Xencor to Present at Upcoming Investor Conferences MONROVIA, Calif. , Oct. 31, 2016 /PRNewswire/ -- Xencor , Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will	View HTML Xencor to Present at Upcoming Investor Conferences 16.6 KB
Toggle SummaryOct 26, 2016	Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 MONROVIA, Calif. , Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter	View HTML Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference Call on November 2, 2016 14 KB
Toggle SummaryOct 03, 2016	Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting Abstract available on the ACR Annual Meeting website	View HTML Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting 74.2 KB
Toggle SummarySep 15, 2016	Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 MONROVIA, Calif. , Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been	View HTML Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195 84.8 KB
Toggle SummarySep 12, 2016	Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies MONROVIA, Calif. , Sept. 12, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been	View HTML Xencor Doses First Patient in Lead Immuno-Oncology Bispecific Program XmAb14045 for the Treatment of Acute Myeloid Leukemia and Other CD123-Expressing Hematologic Malignancies 21.7 KB
Toggle SummaryAug 31, 2016	Xencor to Present at Upcoming Investor Conferences MONROVIA, Calif. , Aug. 31, 2016 /PRNewswire/ -- Xencor , Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will	View HTML Xencor to Present at Upcoming Investor Conferences 16.6 KB

Tools

Press Releases